Results 51 to 60 of about 1,518 (207)

The Impact of Vitiligo on Patients' Quality of Life: Retrospective Observational Study. [PDF]

Int J Dermatol
International Journal of Dermatology, Volume 64, Issue 12, Page 2306-2308, December 2025.
Picone V, Coronella L, Turco M, Cimmino M, Patruno C, Scalvenzi M, Napolitano M.   +6 more
europepmc   +2 more sources

Off-Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives. [PDF]

Exp Dermatol
JAK inhibitors are used to treat various inflammatory skin diseases. However, systemic formulations are associated with an increased risk of major adverse events.
Spadafora M, Morsia S, Di Lernia VG, Kaleci S, Pellacani G, Longo C.   +5 more
europepmc   +3 more sources

Emerging Role of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis [PDF]

, 2020
Background: Atopic dermatitis (AD) is a common chronic, inflammatory skin condition. The pathogenesis of AD involves many cytokines that utilize the Janus kinase/signal transducer and activator of transcription (JAK-STAT) signaling cascade; therefore ...
Feldman, Steven R., Ghamrawi I, Rima, Heron, Courtney E., Singh, Rhea, Strowd, Lindsay C.   +4 more
core   +1 more source

Efficacy of ruxolitinib cream in vitiligo by patient characteristics and affected body areas: Descriptive subgroup analyses from a phase 2, randomized, double-blind trial [PDF]

, 2021
To the Editor: Vitiligo is a chronic autoimmune disease resulting in patches of depigmented skin and reduced quality of life. In a randomized, dose-ranging phase 2 study (NCT03099304) in 157 adult patients, the Janus kinase (JAK) 1/JAK2 inhibitor ...
Butler, Kathleen, Gottlieb, Alice B., Grimes, Pearl, Hamzavi, Iltefat, Harris, John E., Kuo, Fiona I., Lebwohl, Mark, Pandya, Amit G., Rosmarin, David, Sun, Kang   +9 more
core   +1 more source

Ruxolitinib cream monotherapy for facial and/or neck atopic dermatitis: results from a decentralized, randomized phase 2 clinical trial

Journal of Dermatological Treatment
Purpose Ruxolitinib cream was evaluated in patients with facial/neck atopic dermatitis (AD) in a decentralized, double-blind, randomized clinical trial (NCT05127421).Materials and methods Patients aged 12–70 years with AD (Investigator’s Global ...
Zelma C. Chiesa Fuxench, Zhihong Lai, YuTzu Kuo, Haq Nawaz, Jonathan Cotliar   +4 more
doaj   +1 more source

Management of Atopic Dermatitis: Clinical Utility of Ruxolitinib

Journal of Asthma and Allergy, 2022
Shayan Owji,1,2 Stella A Caldas,1,3 Benjamin Ungar1 1Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 2The University of Texas Medical Branch, Galveston, TX, USA; 3George Washington School of Medicine and Health ...
Owji S, Caldas SA, Ungar B
doaj  

Vitiligo: Ruxolitinib and Other Oral Treatment Options Beyond Ruxolitinib. [PDF]

Skin Res Technol
ABSTRACT Background Vitiligo is a chronic autoimmune disorder marked by the loss of melanocytes, causing depigmented patches across the skin. Affecting up to 2% of the global population, vitiligo presents significant psychological impacts, particularly in those with darker skin types. Current hypotheses attribute its etiology to autoimmune destruction,
Ghani H, Tan IJ, Ghofrani S, Tchack M, Rao B.   +4 more
europepmc   +2 more sources

Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies

Journal of Dermatological Treatment
Purpose: Ruxolitinib (selective Janus kinase [JAK] 1 and JAK2 inhibitor) cream demonstrated efficacy and safety in patients with atopic dermatitis (AD) in the phase 3 TRuE-AD studies. In TRuE-AD1/TRuE-AD2 (NCT03745638/NCT03745651), adults and adolescents
Eric L. Simpson, Robert Bissonnette, Zelma C. Chiesa Fuxench, Howard Kallender, Daniel Sturm, Haobo Ren, Linda F. Stein Gold   +6 more
doaj   +1 more source

JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis [PDF]

, 2014
Janus kinase (JAK) pathways are key mediators in the immunopathogenesis of psoriasis. Psoriasis treatment has evolved with the advent of targeted therapies, which inhibit specific components of the psoriasis proinflammatory cascade.
April W. Armstrong, Leeyen Hsu
core   +3 more sources

624 - Vitiligo biomarker CXCL10 correlates with clinical response in the phase 2 randomized, double-blind, vehicle-controlled TRuE-V mechanism of action study [PDF]

: Introduction/Background: Ruxolitinib cream is a topical formulation of the selective Janus kinase (JAK) 1/JAK2 inhibitor ruxolitinib and is the first and only repigmentation treatment approved by ...
Alam, Maryam Shayesteh, Beecker, Jennifer, Ganesan, Anand K, Kornacki, Deanna, Laquer, Vivian T, Lebwohl, Mark, Lynde, Charles, Passeron, Thierry, Smith, Susan H, Soltanalizadeh, Babak, Volkova, Angelina   +10 more
core   +1 more source